A Phase II trial of IMO—3100 in psoriasis (NCT01622348) indicated that, subsequent to treatment, the mRNA levels of IL—17A and CXCL1 in lesional tissues were significantly downregulated, and the proportion of Th17 cells was reduced. This evidence concerns the gene IL17A and psoriasis.